title: Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression.
abstract: Prediction of cancer progression after radical prostatectomy is one of the most challenging problems in the management of prostate cancer. Gene-expression profiling is widely used to identify genes associated with such progression. Usually candidate genes are identified according to a gene-by-gene comparison of expression. Recent reports suggested that relative expression of a gene pair more efficiently predicts cancer progression than single-gene analysis does. The top-scoring pair (TSP) algorithm classifies phenotypes according to the relative expression of a pair of genes. We applied the TSP approach to predict, which patients would experience systemic tumor progression after radical prostatectomy. Relative expression of TPD52L2/SQLE and CEACAM1/BRCA1 gene pairs identified those patients with more than 99% specificity but relatively low sensitivity (approximately 10%). These two gene pairs were validated in three independent data sets. In addition, combining two pairs of genes improved sensitivity without compromising specificity. Functional annotation of the TSP genes showed that they cluster by a limited number of biological functions and pathways, suggesting that relatively lower expression of genes from specific pathways can predict cancer progression. In conclusion, comparative analysis of the expression of two genes may be a simple and effective classifier for prediction of prostate cancer progression. In summary, the TSP approach can be used to identify patients whose prostate cancer will progress after they undergo radical prostatectomy. Two gene pairs can predict which men would experience progression to the metastatic form of the disease. However, because our analysis was based on a relatively small number of genes, a larger study will be needed to identify the best predictors of disease outcome overall.
authors.affiliation: Department of Genitourinary Medical Oncology, The University of Texas MD, Anderson Cancer Center, Houston, TX 77030-4009, USA.
authors.forename: H
authors.initials: H
authors.lastname: Zhao
authors.forename: C J
authors.initials: CJ
authors.lastname: Logothetis
authors.forename: I P
authors.initials: IP
authors.lastname: Gorlov
mesh_terms: D000465:Algorithms; D014408:Biomarkers, Tumor / Q000235:genetics*; D016022:Case-Control Studies; D019295:Computational Biology; D018450:Disease Progression; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D012680:Sensitivity and Specificity; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor
references.citation: PLoS One. 2008;3(5):e2318
references.pmid: 18846227
references.citation: Nat Genet. 2007 Jan;39(1):41-51
references.pmid: 17173048
references.citation: Oncogene. 2006 Aug 17;25(36):4965-74
references.pmid: 16568082
references.citation: Cancer Res. 2002 Aug 1;62(15):4499-506
references.pmid: 12154061
references.citation: Toxicol In Vitro. 2006 Mar;20(2):187-210
references.pmid: 16289744
references.citation: Bioinformatics. 2005 Oct 15;21(20):3905-11
references.pmid: 16131522
references.citation: Prostate Cancer Prostatic Dis. 2009;12(4):333-8
references.pmid: 19901933
references.citation: Nature. 2001 Aug 23;412(6849):822-6
references.pmid: 11518967
references.citation: Bioinformatics. 2005 Oct 15;21(20):3896-904
references.pmid: 16105897
references.citation: Clin Cancer Res. 2009 Mar 1;15(5):1558-65
references.pmid: 19223505
references.citation: FASEB J. 2005 Feb;19(2):243-5
references.pmid: 15548588
references.citation: Oncogene. 2007 Mar 22;26(13):1875-84
references.pmid: 16983333
references.citation: Hum Pathol. 2007 Jul;38(7):1081-1091
references.pmid: 17442374
references.citation: FEBS J. 2008 Nov;275(22):5703-13
references.pmid: 18959755
references.citation: BMC Cancer. 2007 Apr 12;7:64
references.pmid: 17430594
references.citation: Prostate. 2010 Feb 15;70(3):270-5
references.pmid: 19902474
references.citation: Cancer Cell. 2002 Mar;1(2):203-9
references.pmid: 12086878
references.citation: Antioxid Redox Signal. 2000 Fall;2(3):585-605
references.pmid: 11229370
references.citation: Cancer Res. 2007 Jun 1;67(11):5117-25
references.pmid: 17545589
references.citation: Nat Genet. 2007 May;39(5):645-9
references.pmid: 17401363
references.citation: Eur J Hum Genet. 2008 Apr;16(4):496-505
references.pmid: 18231127
references.citation: Cell Res. 2002 Dec;12(5-6):311-20
references.pmid: 12528889
references.citation: Mol Carcinog. 2002 Jan;33(1):25-35
references.pmid: 11807955
references.citation: Urol Oncol. 2011 Mar-Apr;29(2):145-9
references.pmid: 19269198
references.citation: Prostate. 2005 May 15;63(3):240-51
references.pmid: 15538743
references.citation: Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1439-45
references.pmid: 18963536
references.citation: Stat Appl Genet Mol Biol. 2004;3:Article19
references.pmid: 16646797
references.citation: J Clin Oncol. 2004 Jul 15;22(14):2790-9
references.pmid: 15254046